Literature DB >> 18322709

Potent in vitro anti-Trypanosoma cruzi activity of pyridine-2-thiol N-oxide metal complexes having an inhibitory effect on parasite-specific fumarate reductase.

Marisol Vieites1, Pablo Smircich, Beatriz Parajón-Costa, Jorge Rodríguez, Verónica Galaz, Claudio Olea-Azar, Lucía Otero, Gabriela Aguirre, Hugo Cerecetto, Mercedes González, Alicia Gómez-Barrio, Beatriz Garat, Dinorah Gambino.   

Abstract

In the search for new therapeutic tools against Chagas disease (American trypanosomiasis) palladium and platinum complexes of the bioactive ligand pyridine-2-thiol N-oxide were exhaustively characterized and evaluated in vitro. Both complexes showed high in vitro growth inhibition activity (IC(50) values in the nanomolar range) against Trypanosoma cruzi, the causative agent of the disease. They were 39-115 times more active than the antitrypanosomal drug Nifurtimox. The palladium complex showed an approximately threefold enhancement of the activity compared with the parent compound. In addition, owing to their low unspecific cytotoxicity on mammalian cells, the complexes showed a highly selective antiparasite activity. To get an insight into the mechanism of action of these compounds, DNA, redox metabolism (intraparasite free-radical production) and two parasite-specific enzymes absent in the host, namely, trypanothione reductase and NADH-fumarate reductase, were evaluated as potential parasite targets. Additionally, the effect of metal coordination on the free radical scavenger capacity previously reported for the free ligand was studied. All the data strongly suggest that trypanocidal action of the complexes could mainly rely on the inhibition of the parasite-specific enzyme NADH-fumarate reductase.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18322709     DOI: 10.1007/s00775-008-0358-7

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  28 in total

1.  (2,2':6',2"-Terpyridine)platinum(II) complexes are irreversible inhibitors of Trypanosoma cruzi trypanothione reductase but not of human glutathione reductase.

Authors:  S Bonse; J M Richards; S A Ross; G Lowe; R L Krauth-Siegel
Journal:  J Med Chem       Date:  2000-12-14       Impact factor: 7.446

Review 2.  Pharmacological approaches to antitrypanosomal chemotherapy.

Authors:  S L Croft
Journal:  Mem Inst Oswaldo Cruz       Date:  1999 Mar-Apr       Impact factor: 2.743

Review 3.  Chemotherapy of trypanosomiases and leishmaniasis.

Authors:  Simon L Croft; Michael P Barrett; Julio A Urbina
Journal:  Trends Parasitol       Date:  2005-09-08

4.  Novel antitrypanosomal agents based on palladium nitrofurylthiosemicarbazone complexes: DNA and redox metabolism as potential therapeutic targets.

Authors:  Lucía Otero; Marisol Vieites; Lucía Boiani; Ana Denicola; Carolina Rigol; Lucía Opazo; Claudio Olea-Azar; Juan Diego Maya; Antonio Morello; R Luise Krauth-Siegel; Oscar E Piro; Eduardo Castellano; Mercedes González; Dinorah Gambino; Hugo Cerecetto
Journal:  J Med Chem       Date:  2006-06-01       Impact factor: 7.446

5.  Cytotoxicity of (2,2':6',2''-terpyridine)platinum(II) complexes to Leishmania donovani, Trypanosoma cruzi, and Trypanosoma brucei.

Authors:  G Lowe; A S Droz; T Vilaivan; G W Weaver; L Tweedale; J M Pratt; P Rock; V Yardley; S L Croft
Journal:  J Med Chem       Date:  1999-03-25       Impact factor: 7.446

6.  Electrochemical and ESR study of 5-nitrofuryl-containing thiosemicarbazones antiprotozoal drugs.

Authors:  Carolina Rigol; C Olea-Azar; Fernando Mendizábal; Lucía Otero; Dinorah Gambino; Mercedes González; Hugo Cerecetto
Journal:  Spectrochim Acta A Mol Biomol Spectrosc       Date:  2004-12-13       Impact factor: 4.098

7.  Improving anti-trypanosomal activity of 3-aminoquinoxaline-2-carbonitrile N1,N4-dioxide derivatives by complexation with vanadium.

Authors:  Carolina Urquiola; Marisol Vieites; Gabriela Aguirre; Adoración Marín; Beatriz Solano; Gabriel Arrambide; Pabla Noblía; María Laura Lavaggi; María H Torre; Mercedes González; Antonio Monge; Dinorah Gambino; Hugo Cerecetto
Journal:  Bioorg Med Chem       Date:  2006-05-18       Impact factor: 3.641

Review 8.  New metal complexes as potential therapeutics.

Authors:  Christiana Xin Zhang; Stephen J Lippard
Journal:  Curr Opin Chem Biol       Date:  2003-08       Impact factor: 8.822

Review 9.  Metal complexes as chemotherapeutic agents against tropical diseases: trypanosomiasis, malaria and leishmaniasis.

Authors:  Roberto A Sánchez-Delgado; Atilio Anzellotti
Journal:  Mini Rev Med Chem       Date:  2004-01       Impact factor: 3.862

10.  Trypanothione reductase from Trypanosoma cruzi. Catalytic properties of the enzyme and inhibition studies with trypanocidal compounds.

Authors:  M C Jockers-Scherübl; R H Schirmer; R L Krauth-Siegel
Journal:  Eur J Biochem       Date:  1989-03-15
View more
  10 in total

1.  New organoruthenium complexes with bioactive thiosemicarbazones as co-ligands: potential anti-trypanosomal agents.

Authors:  Bruno Demoro; Cynthia Sarniguet; Roberto Sánchez-Delgado; Miriam Rossi; Daniel Liebowitz; Francesco Caruso; Claudio Olea-Azar; Virtudes Moreno; Andrea Medeiros; Marcelo A Comini; Lucía Otero; Dinorah Gambino
Journal:  Dalton Trans       Date:  2011-12-02       Impact factor: 4.390

2.  Searching for new chemotherapies for tropical diseases: ruthenium-clotrimazole complexes display high in vitro activity against Leishmania major and Trypanosoma cruzi and low toxicity toward normal mammalian cells.

Authors:  Alberto Martínez; Teresia Carreon; Eva Iniguez; Atilio Anzellotti; Antonio Sánchez; Marina Tyan; Aaron Sattler; Linda Herrera; Rosa A Maldonado; Roberto A Sánchez-Delgado
Journal:  J Med Chem       Date:  2012-04-09       Impact factor: 7.446

3.  New heteroleptic oxidovanadium(V) complexes: synthesis, characterization and biological evaluation as potential agents against Trypanosoma cruzi.

Authors:  Gonzalo Scalese; Ignacio Machado; Carolina Fontana; Gastón Risi; Gustavo Salinas; Leticia Pérez-Díaz; Dinorah Gambino
Journal:  J Biol Inorg Chem       Date:  2018-09-08       Impact factor: 3.358

4.  Increasing the activity of copper(II) complexes against Leishmania through lipophilicity and pro-oxidant ability.

Authors:  Andressa dos Santos Portas; Danilo Ciccone Miguel; Jenicer K U Yokoyama-Yasunaka; Silvia Reni Bortolin Uliana; Breno Pannia Espósito
Journal:  J Biol Inorg Chem       Date:  2011-08-25       Impact factor: 3.358

5.  Risedronate metal complexes potentially active against Chagas disease.

Authors:  Bruno Demoro; Francesco Caruso; Miriam Rossi; Diego Benítez; Mercedes Gonzalez; Hugo Cerecetto; Beatriz Parajón-Costa; Jorge Castiglioni; Melina Galizzi; Roberto Docampo; Lucía Otero; Dinorah Gambino
Journal:  J Inorg Biochem       Date:  2010-08-14       Impact factor: 4.155

6.  Novel palladium (II) complexes with tetradentate thiosemicarbazones. Synthesis, characterization, in vitro cytotoxicity and xanthine oxidase inhibition.

Authors:  Dilşad Özerkan; Onur Ertik; Buşra Kaya; Serap Erdem Kuruca; Refiye Yanardag; Bahri Ülküseven
Journal:  Invest New Drugs       Date:  2019-03-14       Impact factor: 3.850

7.  Nitro/nitrosyl-ruthenium complexes are potent and selective anti-Trypanosoma cruzi agents causing autophagy and necrotic parasite death.

Authors:  Tanira M Bastos; Marília I F Barbosa; Monize M da Silva; José W da C Júnior; Cássio S Meira; Elisalva T Guimaraes; Javier Ellena; Diogo R M Moreira; Alzir A Batista; Milena B P Soares
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

Review 8.  Facing Diseases Caused by Trypanosomatid Parasites: Rational Design of Pd and Pt Complexes With Bioactive Ligands.

Authors:  Dinorah Gambino; Lucía Otero
Journal:  Front Chem       Date:  2022-01-07       Impact factor: 5.221

Review 9.  Synthetic Medicinal Chemistry in Chagas' Disease: Compounds at The Final Stage of "Hit-To-Lead" Phase.

Authors:  Hugo Cerecetto; Mercedes González
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-25

10.  Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy.

Authors:  Chong Zhao; Xin Chen; Dan Zang; Xiaoying Lan; Siyan Liao; Changshan Yang; Peiquan Zhang; Jinjie Wu; Xiaofen Li; Ningning Liu; Yuning Liao; Hongbiao Huang; Xianping Shi; Lili Jiang; Xiuhua Liu; Zhimin He; Xuejun Wang; Jinbao Liu
Journal:  Biochem Pharmacol       Date:  2016-07-02       Impact factor: 5.858

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.